FGFR2-related pathogenesis and FGFR2-targeted therapeutics (review)

International Journal of Molecular Medicine

Volumn 23, Issue 3, 2009, Pages 307-311

  Katoh, Yuriko ^a   Katoh, Masaru ^b  

^a M&M Medical BioInformatics   (Japan)

^b NATIONAL CANCER CENTER   (Japan)

Author keywords

Chemoradiotherapy; Esophageal cancer; FGF7; Hedgehog; Invasion; KEAP1; Metastasis; Peritoneal dissemination; Ubiquitylation; WNT

Indexed keywords

1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; 3 [4 METHYL 2 (2 OXO 3 INDOLINYLMETHYLIDENYL) 3 PYRROLYL]PROPIONIC ACID; ANTIBODY; ANTINEOPLASTIC AGENT; APTAMER; CEDIRANIB; DEFAKIN; DEFAKIN1; DEFAKIN10; FIBROBLAST GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 2B; KI 23057; MICRORNA; PEPTIDE DERIVATIVE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; ENZYME INHIBITOR; FGFR2 PROTEIN, HUMAN; ISOENZYME; REACTIVE OXYGEN METABOLITE;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; BLADDER CANCER; BREAST CANCER; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENICITY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; ENDOMETRIUM CANCER; GENE FUNCTION; GENE NUMBER; GENE REPRESSION; GENETIC REGULATION; HUMAN; LUNG CANCER; MISSENSE MUTATION; NEOPLASM; NONHUMAN; OVARY CANCER; PATHOGENESIS; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; UTERUS CANCER; ALLELE; ANIMAL; CHROMOSOME 10; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; MOUSE; MOUSE MUTANT; OXIDATIVE STRESS; RISK FACTOR; SIGNAL TRANSDUCTION; SPLICEOSOME; UPREGULATION;

ALLELES; ANIMALS; CHROMOSOMES, HUMAN, PAIR 10; ENZYME INHIBITORS; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOENZYMES; MALE; MICE; MICE, KNOCKOUT; NEOPLASMS; OXIDATIVE STRESS; POLYMORPHISM, SINGLE NUCLEOTIDE; REACTIVE OXYGEN SPECIES; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RISK FACTORS; SIGNAL TRANSDUCTION; SPLICEOSOMES; UP-REGULATION;

EID: 64249151246     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000132     Document Type: Review

References (73)

1. Dionne CA, Crumley G, Bellot F, et al: Cloning and expression of two distinct high-affinity receptors cross-reacting with acidic and basic FGFs. EMBO J 9: 2685-2692, 1990.
2. Miki T, Fleming TP, Bottaro DP, et al: Expression cDNA cloning of the KGF receptor by creation of a transforming autocrine loop. Science 251: 72-75, 1991.
3. Carstens RP, Wagner EJ and Garcia-Blanco MA: An intronic splicing silencer causes skipping of the IIIb exon of Fgfr2 through involvement of polypyrimidine tract binding protein. Mol Cell Biol 20: 7388-7400, 2000.
4. Katoh M and Katoh M: FGFR2 and WDR11 are neighboring oncogene and tumor suppressor gene on human chromosome 10q26. Int J Oncol 22: 1155-1159, 2003.
5. Eswarakumar VP, Lax I and Schlessinger J: Cellular signaling by FGF receptors. Cytokine Growth Factor Rev 16: 139-149, 2005.
6. Dailey L, Ambrosetti D, Mansukhani A and Basilico C: Mechanisms underlying differential responses to FGF signaling. Cytokine Growth Factor Rev 16: 233-247, 2005.
7. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2: 442-454, 2002.
8. Shook D and Keller R: Mechanisms, mechanics and function of epithelial-mesenchymal transitions in early development. Mech Dev 120: 1351-1383, 2003.
9. Lee MJ, Dedhar S, Kalluri R and Thompson EW: The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 172: 973-981, 2006.
10. Ornitz DM, Xu J, Colvin JS, et al: Receptor specificity of the FGF family. J Biol Chem 271: 15292-15297, 1996.
11. Zhang X, Ibrahimi OA, Olsen SK, et al: Receptor specificity of the FGF family. J Biol Chem 281: 15694-15700, 2006.
12. Katoh M: WNT and FGF gene clusters. Int J Oncol 21: 1269-1273, 2002.
13. Katoh M and Katoh M: Evolutionary conservation of CCND1-ORAOV1-FGF19-FGF4 locus from zebrafish to human. Int J Mol Med 12: 45-50, 2003.
14. Popovici C, Roubin R, Coulier F and Birnbaum D: An evolutionary history of the FGF superfamily. Bioessays 27: 849-857, 2005.
15. Katoh Y and Katoh M: Comparative genomics on FGF7, FGF10, FGF22 orthologs, and identification of fgf25. Int J Mol Med 16: 767-770, 2005.
16. Finch PW, Rubin JS, Miki T, et al: Human KGF is FGF-related with properties of a paracrine effector of epithelial cells. Science 145: 752-755, 1989.
17. Boismenu R and Havran WL: Modulation of epithelial cell growth by intraepithelial γδT cells. Science 266: 1253-1255, 1994.
18. auf demKeller U, Krampert M, Kümin A, Braun S and Werner S: Keratinocyte growth factor: effects on keratinocytes and mechanisms of action. Eur J Cell Biol 83: 607-612, 2004.
19. Arman E, Haffner-Krausz R, Gorivodsky M and Lonai P: Fgfr2 is required for limb outgrowth and lung-branching morphogenesis. Proc Natl Acad Sci USA 96: 11895-11899, 1999.
20. Spencer-Dene B, Sala FG, Bellusci S, et al: Stomach development is dependent on FGF10/FGFR2b-mediated signaling. Gastroenterology 130: 1233-1244, 2006.
21. Umemori H, Linhoff MW, Ornitz DM and Sanes JR: FGF22 and its close relatives are presynaptic organizing molecules in the mammalian brain. Cell 118: 257-270, 2004.
22. Katoh M and Katoh M: WNT signaling pathway and stem cell signaling network. Clin Cancer Res 13: 4042-4045, 2007.
23. Katoh M: WNT signaling in stem cell biology and regenerative medicine. Curr Drug Targets 9: 565-570, 2008.
24. Katoh M: Dysregulation of stem cell signaling network due to germline mutation, SNP, Helicobacter pylori infection, epigenetic change, and genetic alteration in gastric cancer. Cancer Biol Ther 6: 832-839, 2007.
25. Katoh M: Cancer genomics and genetics of FGFR2. Int J Oncol 33: 233-237, 2008.
26. Wilkie AOM: Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations. Cytokine Growth Factor Rev 16: 187-203, 2005.
27. Pollock PM, Gartside MG, Dejeza LC, et al: Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 26: 7158-7162, 2007.
28. Davies H, Hunter C, Smith R, et al: Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 65: 7591-7595, 2005.
29. Jang JH, Shin KH and Park JG: Mutations in FGFR2 and FGFR3 genes associated with human gastric and colorectal cancers. Cancer Res 61: 3541-3543, 2001.
30. Adnane J, Gaudray P, Dionne CA, et al: BEK and FLG are amplified in subsets of human breast cancers. Oncogene 6: 659-663, 1991.
31. Katoh M and Terada M: Oncogenes and tumor suppressor genes. In: Gastric Cancer. Nishi M, et al (eds). Springer-Verlag, Tokyo, pp196-208, 1993.
32. Moffa AB, Tannheimer SL and Ethier SP: Transforming potential of alternatively spliced variants of FGFR2 in human mammary epithelial cells. Mol Cancer Res 2: 643-652, 2004.
33. Easton DF, Pooley KA, Dunning AM, et al: Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 447: 1087-1093, 2007.
34. Hunter DJ, Kraft P, Jacobs KB, et al: A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet 39: 870-874, 2007.
35. Huijts PE, Vreeswijk MP, Kroeze-Jansema KH, et al: Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases. Breast Cancer Res 9: R78, 2007.
36. Meyer KB, Maia A-T, O'Reilly M, et al: Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol 6: e108, 2008.
37. McGrath M, Lee IM, Buring J, Hunter DJ and De Vivo I: Novel breast cancer risk alleles and endometrial cancer risk. Int J Cancer 123: 2961-2964, 2008.
38. Gates MA, Tworoger SS, Terry KL, et al: Breast cancer susceptibility alleles and ovarian cancer risk in 2 study populations. Int J Cancer 124: 729-733, 2008.
39. Chaffer CL, Dopheide B, Savagner P, et al: Aberrant FGF receptor signaling in bladder and other cancers. Differentiation 75: 831-842, 2007.
40. Katoh M: Epithelial-mesenchymal transition in gastric cancer. Int J Oncol 27: 1677-1683, 2005.
41. Katoh Y and Katoh M: Hedgehog signaling, epithelial-to-mesenchymal transition, and miRNA. Int J Mol Med 22: 271-275, 2008.
42. Matsubara A, Kan M, Feng S and McKeehan WL: Inhibition of growth of malignant rat prostate tumor cells by restoration of FGFR2. Cancer Res 58: 1509-1514, 1998.
43. Ricol D, Cappellen D, El Marjou A, et al: Tumour suppressive properties of FGFR2b in human bladder cancer. Oncogene 18: 7234-7243, 1999.
44. Grose R, Fantl V, Werner S, et al: The role of Fgfr2b in skin homeostasis and cancer development. EMBO J 26: 1268-1278, 2007.
45. Jameson J, Ugarte K, Chen N, et al: A role for skin γδT cells in wound repair. Science 296: 747-749, 2002.
46. Girardi M, Oppenheim DE, Steele CR, et al: Regulation of cutaneous malignancy by γδT cells. Science 294: 605-609, 2001.
47. Tong KI, Kobayashi A, Katsuoka F and Yamamoto M: Two-site substrate recognition model for the Keap1-Nrf2 system: a hinge and latch mechanism. Biol Chem 387: 1311-1320, 2006.
48. Reardon W, Winter RM, Rutland P, et al: Mutations in the FGFR2 gene cause Crouzon syndrome. Nat Genet 8: 98-103, 1994.
49. Jabs EW, Li X, Scott AF, et al: Jackson-Weiss and Crouzon syndromes are allelic with mutations in FGFR2. Nat Genet 8: 275-279, 1994.
50. Passos-Bueno MR, Wilcox WR, Jabs EW, et al: Clinical spectrum of FGFR mutations. Hum Mutat 14: 115-125, 1999.
51. O'Donovan MC, Norton N, Williams H, et al: Analysis of 10 independent samples provides evidence for association between schizophrenia and a SNP flanking FGFR2. Mol Psychiatry (In press).
52. Nobel ME, Endicott JA and Johnson LN: Protein kinase inhibitors: insight into drug design from structure. Science 303: 1800-1805, 2004.
53. Garber K: The second wave in kinase cancer drugs. Nat Biotechnol 24: 127-130, 2006.
54. Mohammadi M, Froum S, Hamby JM, et al: Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J 17: 5896-5904, 1998.
55. Koziczak M, Holbro T and Hynes NE: Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Oncogene 23: 3501-3508, 2004.
56. Dutt A, Salvesen HB, Chen TH, et al: Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci USA 105: 8713-8717, 2008.
57. Byron SA, Gartside MG, Wellens CL, et al: Inhibition of activated FGFR2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Res 68: 6902-6907, 2008.
58. Sun L, Tran N, Tang F, et al: Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J Med Chem 41: 2588-2603, 1998.
59. Mohammadi M, McMahon G, Sun L, et al: Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 276: 955-960, 1997.
60. Wedge SR, Kendrew J, Hennequin LF, et al: AZD2171: a highly potent, orally bioavailable, VEGFR2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65: 4389-4400, 2005.
61. Nakamura K, Yashiro M, Matsuoka T, et al: A novel molecular targeting compound as FGFR2 phosphorylation inhibitor, Ki23057, for scirrhous gastric cancer. Gastroenterology 131: 1530-1541, 2006.
62. Katoh M: RNA technology targeted to the WNT signaling pathway. Cancer Biol Ther 7: 275-277, 2008.
63. Li S, Christensen C, Kiselyov VV, et al: Fibroblast growth factor-derived peptides: functional agonists of the fibroblast growth factor receptor. J Neurochem 104: 667-682, 2008.
64. Ulrich H: DNA and RNA aptamers as modulators of protein function. Med Chem 1: 199-208, 2005.
65. Lee HK, Choi YS, Park YA and Jeong S: Modulation of oncogenic transcription and alternative splicing by beta-catenin and an RNA aptamer in colon cancer cells. Cancer Res 66: 10560-10566, 2006.
66. Ireson CR and Kelland LR: Discovery and development of anticancer aptamers. Mol Cancer Ther 5: 2957-2962, 2006.
67. Reichert JM, Rosensweig CJ, Faden LB and Dewitz MC: Monoclonal antibody successes in the clinic. Nat Biotechnol 23: 1073-1078, 2005.
68. Fire A, Xu S, Montgomery MK, et al: Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391: 806-811, 1998.
69. Elbashir SM, Harborth J, Lendeckel W, et al: Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411: 494-498, 2001.
70. Liang Z, Wu H, Reddy S, et al: Blockade of invasion and metastasis of breast cancer cells via targeting CXCR4 with an artificial microRNA. Biochem Biophys Res Commun 363: 542-546, 2007.
71. Katoh M: Demand for user-friendly 'omics' web service utilizing next-generation supercomputer in the sequencing era. Mol Cancer Genet 1: 1-2, 2008.
72. Katoh M and Katoh M: Bioinformatics for cancer management in the post-genome era. Technol Cancer Res Treat 5: 169-176, 2006.
73. Collins I and Workman P: New approaches to molecular cancer therapeutics. Nat Chem Biol 12: 689-700, 2006.